Developer docs
API playgroundTry for free, no card

Search company profiles

Precise Bio

Full company profile

uuid0002bjj

Namestring
Precise Bio
Legal namestring
Precise Bio, Inc.
Websiteurl
precise-bio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Precise Bio is a clinical-stage regenerative medicine company developing and commercializing 4D bio-fabricated functional tissues and organs, with a primary focus on ophthalmological applications. The company's lead product, PB-001, is the world's first 3D bio-printed corneal implant manufactured from cultured human corneal cells rather than donor tissue, directly addressing the global shortage of donor corneas. The proprietary bio-fabrication platform enables repeatable, scalable production of lab-grown tissue implants designed to reduce reliance on human donors and mitigate rejection risks associated with traditional donor tissue.

PB-001 is currently being evaluated in a Phase 1 clinical trial at Rambam Medical Center in Haifa, Israel, under authorization from Israel's Ministry of Health. Three patients have been successfully transplanted to date, with the first patient, who was blind, experiencing dramatic vision restoration and no serious adverse events reported across the procedures. The company plans to enroll approximately 10 to 15 patients total, with topline results expected in Q4 2026. Precise Bio has received support from the Israel Innovation Authority as part of Israel's National Bioconvergence Program.

The company's business model is structured around eventual commercialization of bio-printed corneal implants to healthcare providers, hospitals, and ophthalmology centers upon regulatory approval, following a traditional medical device and pharmaceutical pathway. The company is privately held and venture-backed, having raised approximately $27.5 million across disclosed funding rounds including a $12 million round led by Carl Zeiss Meditec. Revenue generation is contingent on successful clinical trial outcomes and subsequent regulatory clearances in target markets, with the broader corneal implants market projected to reach $2.01 billion by 2030.

Short descriptiontext

Precise Bio is a clinical-stage regenerative medicine company developing 3D bio-printed corneal implants via its proprietary bio-fabrication platform. Its lead product PB-001, designed to address donor cornea shortages, is currently in Phase 1 clinical trials in Israel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGreensboro, United States
HQ citystring
Greensboro
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D bio-printed corneas, regenerative ophthalmology, bio-fabricated tissue implants, cultured corneal cells, ophthalmic medical devices
Industry3 codes
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine — Ophthalmic Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
13D-Bio-Printed Corneal Implants
TypeOne Time License
Description

Once regulatory approvals are obtained, the company expects to generate revenue from the sale of its 3D-bio-printed corneal implants (PB-001) to healthcare providers and hospitals for corneal transplant procedures.

biospace.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PB-001
Description

The world's first bio-printed corneal implant to enter human clinical trials, developed using Precise Bio's bio-fabrication platform from cultured human corneal cells.

biospace.com
Core offering1 text field

Precise Bio is a clinical-stage regenerative medicine company that develops and commercializes 4D bio-fabricated functional tissues and organs, with its lead product being PB-001, the world's first 3D bio-printed corneal implant made from cultured human corneal cells. The implant is currently in Phase 1 clinical trials in Israel to restore vision in patients suffering from corneal blindness. The proprietary bio-fabrication platform enables scalable manufacturing of lab-grown corneal implants to address the global shortage of donor corneas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First patient who was blind experienced dramatic vision restoration following PB-001 transplant
+1 more record
Product overview1 text field

Precise Bio is a clinical-stage regenerative medicine company specializing in bio-printed tissues with a focus on ophthalmology. The company's primary product is PB-001, the world's first 3D-bio-printed corneal implant, which has entered human clinical trials. The technology utilizes a proprietary bio-fabrication platform that manufactures implants from cultured human corneal cells. This platform enables the production of lab-grown tissue implants to address donor shortages and expand access to corneal transplants.

Product and service1 record
1PB-001 3D Bio-Printed Corneal Implant
CategoryRegenerative Ophthalmology — Bio-printed Tissue Implants
Description

The world's first 3D bio-printed corneal implant, manufactured from cultured human corneal cells using Precise Bio's proprietary bio-fabrication platform. Currently in Phase 1 clinical trials to restore vision in patients with corneal blindness or severe vision impairment, addressing the global shortage of donor corneas.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Rambam Medical Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Primary clinical trial site for Phase 1 study of PB-001 3D-bio-printed corneal implant. Medical center in Haifa, Israel received authorization from Israel's Ministry of Health to conduct the transplant procedures. The first patient, who was blind, experienced dramatic vision restoration following the procedure.

globenewswire.com
Strategic tierCoreTypeOthers
Description

Regulatory authority that authorized advancement of Phase 1 clinical trial and provided oversight for the 3D-bio-printed corneal implant transplantation procedures.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Carl Zeiss Meditec
TypeBroad incumbent
Description

Global leader in ophthalmic surgical devices and diagnostics. Carl Zeiss Meditec led Precise Bio's $12M funding round and is a strategic investor validating the corneal implant thesis. Comparable as both an incumbent ophthalmic franchise and a key commercial partner candidate.

TypeDirect peer
Description

Leading provider of donor corneal tissue for transplantation in the US. Directly comparable as it serves the same patient population (corneal blindness) that Precise Bio targets with PB-001, and is the incumbent whose supply scarcity Precise Bio's bio-printed alternative is designed to displace.

3TissueTech
TypeDirect peer
Description

Regenerative medicine company focused on ocular surface diseases using placental tissue technology. Comparable as a clinical/commercial regenerative ophthalmology peer addressing corneal and ocular surface conditions, overlapping with Precise Bio's target indications.

4Aspect Biosystems
TypeDirect peer
Description

Bioprinting platform company developing 3D-printed tissue therapeutics, with programs in metabolic disease and ophthalmology. Comparable as a direct peer in the 3D bioprinting of human tissues space, pursuing similar regenerative medicine outcomes through a different pipeline.

TypeDirect peer
Description

Bioprinting-focused life sciences company providing bioinks, 3D bioprinters, and tissue engineering services. Comparable as a peer in the 3D bioprinting tools and tissue fabrication space that supplies and partners with regenerative medicine developers including those in ophthalmology.

TypeBroad incumbent
Description

Commercial-stage regenerative medicine company marketing bioengineered skin and wound care products. Comparable as a broader regenerative medicine incumbent demonstrating the commercial viability of cell-based tissue products and a potential acquirer or strategic partner for Precise Bio.

TypeEmerging player
Description

Commercial-stage cell therapy company developing autologous and allogeneic cellular products for cartilage repair and burn treatment. Comparable as a clinical-to-commercial cell therapy peer providing insight into regulatory pathway and capital requirements for advanced tissue products.

TypeEmerging player
Description

Regenerative medicine company commercializing placental tissue allografts for wound care and surgical recovery. Comparable as a peer in the regenerative tissue products space addressing surgical applications with a more advanced commercial stage than Precise Bio.

TypeDirect peer
Description

Israeli ophthalmic implant developer with a synthetic corneal implant (CorNeat KPro) that has entered human clinical use. Comparable as a direct competitor in the corneal restoration space, offering a non-biological alternative to Precise Bio's bio-printed PB-001 implant.

TypeBroad incumbent
Description

Major 3D printing company with a healthcare division producing patient-specific surgical models, implants, and bioprinting research collaborations. Comparable as a broad incumbent in 3D printing healthcare applications and a potential partner or acquirer for bioprinting assets like Precise Bio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Precise Bio

Regenerative Medicine — Ophthalmic Medical Devicesprecise-bio.com

Precise Bio is a clinical-stage regenerative medicine company developing 3D bio-printed corneal implants via its proprietary bio-fabrication platform. Its lead product PB-001, designed to address donor cornea shortages, is currently in Phase 1 clinical trials in Israel.

What Precise Bio does

Precise Bio is a clinical-stage regenerative medicine company developing and commercializing 4D bio-fabricated functional tissues and organs, with a primary focus on ophthalmological applications. The company's lead product, PB-001, is the world's first 3D bio-printed corneal implant manufactured from cultured human corneal cells rather than donor tissue, directly addressing the global shortage of donor corneas. The proprietary bio-fabrication platform enables repeatable, scalable production of lab-grown tissue implants designed to reduce reliance on human donors and mitigate rejection risks associated with traditional donor tissue.

PB-001 is currently being evaluated in a Phase 1 clinical trial at Rambam Medical Center in Haifa, Israel, under authorization from Israel's Ministry of Health. Three patients have been successfully transplanted to date, with the first patient, who was blind, experiencing dramatic vision restoration and no serious adverse events reported across the procedures. The company plans to enroll approximately 10 to 15 patients total, with topline results expected in Q4 2026. Precise Bio has received support from the Israel Innovation Authority as part of Israel's National Bioconvergence Program.

The company's business model is structured around eventual commercialization of bio-printed corneal implants to healthcare providers, hospitals, and ophthalmology centers upon regulatory approval, following a traditional medical device and pharmaceutical pathway. The company is privately held and venture-backed, having raised approximately $27.5 million across disclosed funding rounds including a $12 million round led by Carl Zeiss Meditec. Revenue generation is contingent on successful clinical trial outcomes and subsequent regulatory clearances in target markets, with the broader corneal implants market projected to reach $2.01 billion by 2030.

Precise Bio firmographics

Firmographics
Name
Precise Bio
Legal name
Precise Bio, Inc.
Website
https://precise-bio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Precise Bio is a clinical-stage regenerative medicine company developing 3D bio-printed corneal implants via its proprietary bio-fabrication platform. Its lead product PB-001, designed to address donor cornea shortages, is currently in Phase 1 clinical trials in Israel.
Ownership category
akta.pro rank

Precise Bio industry classification

Industry
Product category
Regenerative Medicine — Ophthalmic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • 3D bio-printed corneas
  • Regenerative ophthalmology
  • Bio-fabricated tissue implants
  • Cultured corneal cells
  • Ophthalmic medical devices

Where Precise Bio is headquartered

Location

Headquarters

HQ city
Greensboro
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Precise Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. 3D-Bio-Printed Corneal Implants: Once regulatory approvals are obtained, the company expects to generate revenue from the sale of its 3D-bio-printed corneal implants (PB-001) to healthcare providers and hospitals for corneal transplant procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Precise Bio product offering

Product offering

Core offering

Precise Bio is a clinical-stage regenerative medicine company that develops and commercializes 4D bio-fabricated functional tissues and organs, with its lead product being PB-001, the world's first 3D bio-printed corneal implant made from cultured human corneal cells. The implant is currently in Phase 1 clinical trials in Israel to restore vision in patients suffering from corneal blindness. The proprietary bio-fabrication platform enables scalable manufacturing of lab-grown corneal implants to address the global shortage of donor corneas.

Product overview

Precise Bio is a clinical-stage regenerative medicine company specializing in bio-printed tissues with a focus on ophthalmology. The company's primary product is PB-001, the world's first 3D-bio-printed corneal implant, which has entered human clinical trials. The technology utilizes a proprietary bio-fabrication platform that manufactures implants from cultured human corneal cells. This platform enables the production of lab-grown tissue implants to address donor shortages and expand access to corneal transplants.

Differentiator

Problem solved

Functional benefit

Brands

  • PB-001: The world's first bio-printed corneal implant to enter human clinical trials, developed using Precise Bio's bio-fabrication platform from cultured human corneal cells.

Products and services

  • PB-001 3D Bio-Printed Corneal Implant The world's first 3D bio-printed corneal implant, manufactured from cultured human corneal cells using Precise Bio's proprietary bio-fabrication platform. Currently in Phase 1 clinical trials to restore vision in patients with corneal blindness or severe vision impairment, addressing the global shortage of donor corneas.

Quantifiable outcome

  • First patient who was blind experienced dramatic vision restoration following PB-001 transplant
  • +1 more outcomes

Companies that use Precise Bio

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Precise Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Precise Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Rambam Medical CentercoreStrategic or Co-development Partner · 23 February 2026Primary clinical trial site for Phase 1 study of PB-001 3D-bio-printed corneal implant. Medical center in Haifa, Israel received authorization from Israel's Ministry of Health to conduct the transplant procedures. The first patient, who was blind, experienced dramatic vision restoration following the procedure.
  • Israel Ministry of HealthcoreOthersRegulatory authority that authorized advancement of Phase 1 clinical trial and provided oversight for the 3D-bio-printed corneal implant transplantation procedures.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Precise Bio competitors and assessment

Company assessment

Broad incumbents

  • Carl Zeiss Meditec: Global leader in ophthalmic surgical devices and diagnostics. Carl Zeiss Meditec led Precise Bio's $12M funding round and is a strategic investor validating the corneal implant thesis. Comparable as both an incumbent ophthalmic franchise and a key commercial partner candidate.
  • Organogenesis: Commercial-stage regenerative medicine company marketing bioengineered skin and wound care products. Comparable as a broader regenerative medicine incumbent demonstrating the commercial viability of cell-based tissue products and a potential acquirer or strategic partner for Precise Bio.
  • 3D Systems: Major 3D printing company with a healthcare division producing patient-specific surgical models, implants, and bioprinting research collaborations. Comparable as a broad incumbent in 3D printing healthcare applications and a potential partner or acquirer for bioprinting assets like Precise Bio.

Direct peers

  • CorneaGen: Leading provider of donor corneal tissue for transplantation in the US. Directly comparable as it serves the same patient population (corneal blindness) that Precise Bio targets with PB-001, and is the incumbent whose supply scarcity Precise Bio's bio-printed alternative is designed to displace.
  • TissueTech: Regenerative medicine company focused on ocular surface diseases using placental tissue technology. Comparable as a clinical/commercial regenerative ophthalmology peer addressing corneal and ocular surface conditions, overlapping with Precise Bio's target indications.
  • Aspect Biosystems: Bioprinting platform company developing 3D-printed tissue therapeutics, with programs in metabolic disease and ophthalmology. Comparable as a direct peer in the 3D bioprinting of human tissues space, pursuing similar regenerative medicine outcomes through a different pipeline.
  • BICO (CELLINK): Bioprinting-focused life sciences company providing bioinks, 3D bioprinters, and tissue engineering services. Comparable as a peer in the 3D bioprinting tools and tissue fabrication space that supplies and partners with regenerative medicine developers including those in ophthalmology.
  • CorNeat Vision: Israeli ophthalmic implant developer with a synthetic corneal implant (CorNeat KPro) that has entered human clinical use. Comparable as a direct competitor in the corneal restoration space, offering a non-biological alternative to Precise Bio's bio-printed PB-001 implant.

Emerging players

  • Vericel: Commercial-stage cell therapy company developing autologous and allogeneic cellular products for cartilage repair and burn treatment. Comparable as a clinical-to-commercial cell therapy peer providing insight into regulatory pathway and capital requirements for advanced tissue products.
  • MiMedx: Regenerative medicine company commercializing placental tissue allografts for wound care and surgical recovery. Comparable as a peer in the regenerative tissue products space addressing surgical applications with a more advanced commercial stage than Precise Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Precise Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Precise Bio leadership team

Management profile

Number of profiles

Profiles1 record

Precise Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Precise Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precise Bio

What does Precise Bio do?

Precise Bio is a clinical-stage regenerative medicine company that develops and commercializes 4D bio-fabricated functional tissues and organs, with its lead product being PB-001, the world's first 3D bio-printed corneal implant made from cultured human corneal cells. The implant is currently in Phase 1 clinical trials in Israel to restore vision in patients suffering from corneal blindness. The proprietary bio-fabrication platform enables scalable manufacturing of lab-grown corneal implants to address the global shortage of donor corneas.

Is Precise Bio a public or private company?

Precise Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Precise Bio founded?

Precise Bio was founded in 2015. It employs 11 to 50 people.

Where is Precise Bio based?

Precise Bio is headquartered in Greensboro, United States, in the North America region.

How does Precise Bio make money?

One revenue line is on record: 3D-Bio-Printed Corneal Implants.

Who are Precise Bio's main competitors?

Broad incumbents on record are Carl Zeiss Meditec, Organogenesis and 3D Systems. Direct peers are CorneaGen, TissueTech, Aspect Biosystems, BICO (CELLINK) and CorNeat Vision. Emerging players are Vericel and MiMedx.

Does Precise Bio have an API?

No public API is recorded for Precise Bio.

What industry is Precise Bio in?

Precise Bio's product category is Regenerative Medicine — Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 339113 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
livescience.comMeet the scientists 3D printing corneas to restore people's vision, potentially filling a worldwide shortage of transplantable tissuePrecise Bio, an Israeli and North Carolina-based regenerative medicine company, has successfully performed the first corneal transplant using a 3D-bioprinted implant made from human cells. The procedure addresses the global shortage of donor tissue by allowing a single donor's cells to generate hundreds of implants, with current Phase I trials underway in Israel involving five patients. The company plans to submit an Investigational New Drug application to the U.S. FDA after completing the trial in 2026, aiming for commercial distribution in the U.S. by 2030.GlobeNewswirePrecise Bio Announces Successful Transplantation of Additional Patients in Ongoing Clinical Study of 3D-Bio-Printed Corneal ImplantPrecise Bio announced successful transplantation of the second and third patients with its 3D-bio-printed corneal implant PB-001 at Rambam Medical Center in Israel, following authorization from Israel's Ministry of Health to advance the Phase 1 clinical trial. The first treated patient, who was blind, has experienced dramatic vision restoration, with no serious adverse events reported across all three procedures. The company plans to enroll approximately 10 to 15 patients total and expects topline results in Q4 2026.GlobeNewswirePrecise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferencePrecise Bio, a clinical-stage regenerative medicine company specializing in bio-printed tissues with a focus on ophthalmology, announced that Co-Founder and CEO Aryeh Batt will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company's executive team will also be available for one-on-one meetings with investors during the virtual conference. The announcement is informational and does not disclose any new financial results, pipeline milestones, or strategic developments.BioSpacePrecise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferencePrecise Bio, a clinical-stage regenerative medicine company focused on bio-printed tissues and organs in ophthalmology, announced that Co-Founder and CEO Aryeh Batt will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company stated that its executive team will also be available for one-on-one meetings with investors throughout the virtual conference. Precise Bio's lead program PB-001 is the world's first bio-printed corneal implant to enter human clinical trials.ynetnewsFrom sniffing cancer to printing organs: Biology and tech are colliding in IsraelIsraeli companies Spot It Early and Precise Bio are advancing bio-convergence technologies, with Spot It Early developing a cancer screening test using trained beagles and AI to detect odor patterns in breath samples, achieving 94.8% accuracy in a company-conducted clinical study, while Precise Bio became the first company globally to 3D print a human cornea and successfully transplanted it into a patient at Rambam Medical Center in Haifa. Both companies are running trials with support from the Israel Innovation Authority and the Israeli Ministry of Health, which is aligning its regulatory framework with the US FDA to facilitate approvals. Israel's national bio-convergence initiative, formalized in 2024, is directing government funding toward combining biology, engineering, and computation to address healthcare challenges including cancer early detection and organ transplantation.3DnativesInside the World’s First Successful 3D Bioprinted Human Cornea TransplantRambam Health Care Campus in Israel successfully performed the world's first transplant of a fully 3D bioprinted human cornea implant developed by Precise Bio. The procedure, conducted during a Phase 1 clinical trial, restored vision in a legally blind patient using tissue created from living human cells without donor tissue. This milestone addresses the global shortage of donor corneas and marks a significant advancement in regenerative medicine.Good News NetworkFirst Human Cornea Transplant Using 3D Printed, Lab-Grown Tissue Restores Sight in a ‘Game Changer’ for Millions Who are BlindThe first successful human implant of a 3D-printed cornea created from lab-grown human eye cells has restored a patient's sight, marking a significant milestone in addressing the shortage of donor tissue. Developed by Precise Bio, this innovative cornea could potentially produce hundreds of grafts from a single donated cornea, transforming the transplant landscape. The procedure was performed on October 29, and it represents a turning point for those with corneal blindness, offering hope for effective treatment options in the future.Fox News3D printed cornea restores sight in world firstSurgeons at Rambam Eye Institute in Israel successfully restored sight to a legally blind patient using a fully 3D printed corneal implant grown from cultured human corneal cells, marking the first time an implant that did not rely on donor tissue was transplanted into a human eye. The cornea came from a healthy deceased donor and was multiplied in the lab, allowing researchers to print approximately 300 transparent implants using Precise Bio's regenerative platform. This breakthrough, part of an ongoing Phase 1 clinical trial, could potentially transform access to sight-saving care by addressing global donor tissue shortages.heise online3D-printed cornea allows patient to see againA 3D-printed corneal implant, produced by Israeli company Precise Bio, was successfully transplanted into a patient at the Rambam Eye Institute in Haifa, restoring her vision. This marks the first time such an implant, created from human corneal cells, has been used in a human transplant. The breakthrough could significantly increase the availability of corneal transplants by allowing up to 300 implants to be made from a single donor cornea.Eyes On EyecarePrecise Bio performs first transplant with 3D-printed cornea implantPrecise Bio, Inc. reported that the first patient has successfully received a transplant of its 3D-bio-printed corneal implant as part of a phase 1 clinical trial that began on October 29. This innovative cornea graft, known as PB-001, aims to replace donor corneas and could potentially address corneal blindness in millions of patients. The company plans to release topline data from the trial in the second half of 2026, highlighting the significance of this advancement in ophthalmology.